A Randomized, Placebo-Controlled Trial in Tunisia Treating Cutaneous Leishmaniasis with Paromomycin Ointment

Salah, Afif Ben; Zakraoui, H; Zaâtour, Amor; A, Ftaïti; Zaafouri, B; Garraoui, A; Olliaro, Piero; Dellagi, Koussay; Ismail, Rasimah

doi:10.4269/ajtmh.1995.53.162

Cited by 92 publications

(56 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…serve as animal reservoir hosts. Some countries of the region have endemic foci of zoonotic and anthroponotic cutaneous leishmaniasis, which could cause epidemics among non-immune populations if they are involved in the transmission cycle (Ben Salah et al 1995).…”

Section: Leishmaniasis In North African Regionmentioning

confidence: 99%

Leishmaniasis in northern and western Africa: a review

Kimutai¹,

Ngure²,

Tonui³

et al. 2010

African Journal of Infectious Diseases

View full text Add to dashboard Cite

Leishmaniasis, one of the highly neglected diseases is currently a significant health problem in northern Africa with a rising concern in western Africa because of co-infection with the Human Immunodeficiency Virus (HIV). In this review, we present a summarized analysis of the epidemiology, infective species, parasites reservoirs, diagnosis, treatment and control measures of leishmaniasis in northern and western Africa region. In northern Africa, the disease is prevalent in Morocco, Algeria, Tunisia, Egypt and Libya. Comparatively, there are low prevalence rates of the disease in West African countries including Cameroon, Ghana, Burkina Faso, Niger, Mali, Nigeria and Senegal. In North Africa, visceral leishmaniasis (VL) is caused by L. infantum and transmitted by Phlebotomus perniciosus and P. longicuspis. On the other hand, cutaneous leishmaniasis (CL) is mainly caused by L. major and transmitted by P. papatasi, P. duboscqi and P. pedifer with L. infantum and L. tropica causing lower incidences of the disease. Notably, Algeria is one of the countries that constitute 90% of CL cases worldwide. In Western Africa; CL is caused by L. major while VL is caused by L. donovani. In these regions, zoonotic and anthroponotic cutaneous and visceral leishmaniasis is a health problem that should be addressed urgently.

show abstract

Section: Leishmaniasis In North African Regionmentioning

confidence: 99%

Leishmaniasis in northern and western Africa: a review

Kimutai¹,

Ngure²,

Tonui³

et al. 2010

African Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Diverse preparations of topical PR have been tested on CL in animals and humans. Randomized, placebo-controlled trials that used 15% PR plus 10% urea topically applied during 2 weeks, for example, have been conducted in Tunisia, 6 Iran, 7 and Honduras. 8 The topical application of PR (15%) plus methylbenzethonium chloride (MBCL; 12%) in a soft paraffin-based ointment was effective against Leishmania major in both experimental animals and in humans.…”

Section: Introductionmentioning

confidence: 99%

Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala.

Arana¹,

Mendoza²,

Rizzo³

et al. 2001

The American Journal of Tropical Medicine and Hygiene

114

View full text Add to dashboard Cite

Abstract. A double-blind, randomized trial was undertaken in Guatemala to determine the therapeutic efficacy of an ointment for the treatment of cutaneous leishmaniasis that contained 15% paromomycin and 12% methylbenzethonium chloride and that was applied twice a day for 20 days. The treatment group included 35 patients, and the placebo group included 33 patients. The initial clinical response rate (13 weeks after completing the treatment) was 91.4% in the treatment group and 39.4% in the placebo group. The final clinical response rate at the 12-month followup examination was 85.7% (31 of 35) in the treatment group and 39.4% (13 of 33) in the placebo group (P Յ 0.001). In general, the treatment was well tolerated and was never interrupted because of adverse effects. The number of adverse effects reported in the placebo group was lower than in the treatment group (16 events versus 30 events). All adverse effects reported by patients disappeared within 1 week of completing the treatment. Our findings show that the combination of paromomycin with methylbenzethonium chloride for 20 days is a good alternative for antimonial treatments of cutaneous leishmaniasis in Guatemala.

show abstract

“…Na Tunísia também se observou melhora das lesões ao final do tratamento com PA tópica, embora não tenha havido cura significativa 20 .…”

Section: Discussionunclassified

Efeito de uma formulação hidrofílica de paromomicina tópica na leishmaniose cutânea em pacientes com contra-indicações de tratamento com antimonial pentavalente

Santos

Noronha

Ferreira

et al. 2008

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Revista da Sociedade Brasileira de Medicina Tropical 41(5):444-448, set-out, 2008 ARTIGO/ARTICLEO tratamento ambulatorial da leishmaniose tegumentar no Brasil, realizado com o antimoniato de meglumina (AM) durante 20 a 30 dias, apresenta toxicidade relativamente freqüente. Os efeitos mais relevantes são mialgias, artralgias, anorexia, febre, alterações eletrocardiográficas e alterações bioquímicas da função hepática, renal e pancreática e impedem a aplicação segura em pessoas com ABSTRACTThe therapeutic effect of and adverse events associated with topical use of 10% paromomycin gel on cutaneous leishmaniasis are described. Fifteen patients with cutaneous leishmaniasis fulfilled the following inclusion criteria: contraindication for the use of meglumine antimoniate, positive Montenegro skin test and up to four ulcerated lesions. The formula was prescribed twice a day for 20 days. Fourteen patients were available for the therapeutic outcome evaluation. The cure rate was 21.4% (3/14); 50% improved as far as complete epithelialization; and the failure rate was 28.6%. Nine patients who did not initially present cure were retreated. Eight received a new series of topical paromomycin and one was treated with meglumine antimoniate. Two patients did not receive any new treatment and had continuous slow improvement. Five out of the eight patients retreated with topical paromomycin achieved clinical cure, and three presented failure, including one patient who had shown any improvement with the first treatment. For 53.3% of the patients, the adverse events were mild and local and never led to treatment suspension.

show abstract

A Randomized, Placebo-Controlled Trial in Tunisia Treating Cutaneous Leishmaniasis with Paromomycin Ointment

Cited by 92 publications

References 0 publications

Leishmaniasis in northern and western Africa: a review

Leishmaniasis in northern and western Africa: a review

Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala.

Efeito de uma formulação hidrofílica de paromomicina tópica na leishmaniose cutânea em pacientes com contra-indicações de tratamento com antimonial pentavalente

Contact Info

Product

Resources

About